325 related articles for article (PubMed ID: 30371946)
1. An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus.
Stockmann C; Olson J; Rashid J; Lubsch L; Young DC; Hersh AL; Frymoyer A; Ampofo K; Liu X; Wang Y; Sherwin CMT; Zobell JT
J Clin Pharmacol; 2019 Feb; 59(2):198-205. PubMed ID: 30371946
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Monitoring of Vancomycin in Cystic Fibrosis: Is It Time to Move Past Trough Concentrations?
Fusco NM; Prescott WA; Meaney CJ
Pediatr Infect Dis J; 2019 Mar; 38(3):258-262. PubMed ID: 29742643
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data.
Fewel N
J Clin Pharm Ther; 2021 Oct; 46(5):1426-1432. PubMed ID: 34169543
[TBL] [Abstract][Full Text] [Related]
5. Impact of model-informed precision dosing on achievement of vancomycin exposure targets in pediatric patients with cystic fibrosis.
Frymoyer A; Schwenk HT; Brockmeyer JM; Bio L
Pharmacotherapy; 2023 Oct; 43(10):1007-1014. PubMed ID: 37401162
[TBL] [Abstract][Full Text] [Related]
6. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis.
Santos RP; Prestidge CB; Brown ME; Urbancyzk B; Murphey DK; Salvatore CM; Jafri HS; McCracken GH; Ahmad N; Sanchez PJ; Siegel JD
Pediatr Pulmonol; 2009 Feb; 44(2):148-54. PubMed ID: 19137597
[TBL] [Abstract][Full Text] [Related]
8. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
9. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis.
Yellepeddi VK; Lindley B; Radetich E; Kumar S; Bhakta Z; Leclair L; Parrot M; Young DC
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0099223. PubMed ID: 38059634
[TBL] [Abstract][Full Text] [Related]
11. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
[TBL] [Abstract][Full Text] [Related]
12. Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis.
Fusco NM; Francisconi R; Meaney CJ; Duman D; Frederick CA; Prescott WA
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e103-e108. PubMed ID: 28903517
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
Fusco NM; Toussaint KA; Prescott WA
Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
[TBL] [Abstract][Full Text] [Related]
14. Validation of a pediatric population pharmacokinetic model for vancomycin.
Hahn A; Frenck RW; Zou Y; Vinks AA
Ther Drug Monit; 2015 Jun; 37(3):413-6. PubMed ID: 25423413
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
16. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
[TBL] [Abstract][Full Text] [Related]
17. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
18. The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant
Stoessel AM; Hale CM; Seabury RW; Miller CD; Steele JM
J Pharm Pract; 2019 Aug; 32(4):442-446. PubMed ID: 29554847
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.
Hahn A; Frenck RW; Allen-Staat M; Zou Y; Vinks AA
Ther Drug Monit; 2015 Oct; 37(5):619-25. PubMed ID: 26378371
[TBL] [Abstract][Full Text] [Related]
20. Assessment of an online calculator's vancomycin dosing and exposure appropriateness in persons who inject drugs with methicillin-resistant Staphylococcus aureus bloodstream infections.
Opitz BJ; Housman ST; Housman EL; Lorenzo MP
J Clin Pharm Ther; 2022 Jun; 47(6):752-758. PubMed ID: 34981545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
